• HECTD3 is overexpressed in a majority of breast cancer cases (73-75%) compared to normal tissue (41%).
• Positive HECTD3 expression correlates with lower lymph node metastasis, better tumor differentiation, and smaller tumor size.
• HECTD3 may serve as a prognostic biomarker indicating good prognosis in breast cancer.
• The study provides evidence that HECTD3 could be a potential therapeutic target or diagnostic marker.